

AccuVert™ HCV Seroconversion Panel 0610-0223 (PHV924)

INTENDED USE

The AccuVert™ HCV Seroconversion Panel 0610-0223 (PHV924) is a group of serial bleeds from an individual plasma donor during seroconversion. This panel is intended for use by diagnostic manufacturers and clinical laboratorians in evaluating their HCV test systems with well-characterized specimens. Comprehensive data are provided for comparative analysis. For Research Use Only. Not for use in diagnostic procedures.

PRODUCT DESCRIPTION

This product consists of a set of six undiluted samples from a single plasma donor collected during a period of HCV seroconversion. All units were maintained in a frozen state, except for the interval of dispensing into vials. No preservatives were added.

Item No. 0610-0223 1 vial per member

6 members, 1.2 mL per vial

STORAGE

Panel members should be stored at -20 °C or colder to preserve HCV antibody. Storage at -70 °C or colder is recommended to preserve HCV RNA levels. SeraCare recommends that the samples be divided into smaller aliquots for ease in repeated testing and to avoid multiple freeze-thaw cycles. If turbidity or particulate matter is observed, the samples should be centrifuged in accordance with each test kit manufacturer's instructions for sample preparation.

INTERPRETATION OF RESULTS

The data sheet for AccuVert HCV Seroconversion Panel 0610-0223 (PHV924) is available at www.seracare.com. The data sheet lists results for panel members generated using commercially available screening, monitoring and confirmatory tests approved in the U.S. and/or the European Union. The tests that are listed were performed at SeraCare or at recognized reference laboratories (RL) by individuals who routinely use these procedures. Information regarding specific test methods is available on the data sheet.

LIMITATIONS

AccuVert HCV Seroconversion Panel 0610-0223 (PHV924) is offered for research use only. Not for use in diagnostic procedures. Data are provided for informational purposes. SeraCare Life Sciences does not claim that others can duplicate test results exactly.

PRECAUTIONS

These materials have not been treated and should be considered biohazardous. Follow Universal Precautions¹. Panel members were tested and some were found positive by tests for anti-HCV and HCV RNA. Panel members were tested and found negative for HBsAg and anti-HIV. This does not ensure the absence of these or other human pathogens.

Do not pipette by mouth. Do not smoke, eat, or drink in areas where specimens are handled.

These materials should be disposed of in a manner that will inactivate pathogenic agents.

REFERENCES

1. Siegel JD, Rhinehart E, Jackson M, Chiarello L, and the Healthcare Infection Control Practices Advisory Committee, 2007 Guideline for Isolation Precautions: Preventing Transmission of Infectious Agents in Healthcare Settings.

For assistance, contact SeraCare at 508.244.6400.

The package insert for this panel can be found at www.seracare.com

A printed copy of the package insert or data sheet may be requested by email at info@seracare.com or by phone at 508.244.6400

SeraCare.com

12571-02 March 2017

508.244.6400 • 800.676.1881 Toll Free • 508.634.3334 Fax